What is AOD9604, and why was it developed?
AOD9604 is a synthetic peptide based on a small part of human growth hormone. It contains 16 amino acids: residues 177 to 191 of growth hormone, with an added tyrosine at the beginning. It is not the full hormone. Human research report.
Researchers wanted to separate effects on fat metabolism from the broader effects of growth hormone. That was a reasonable question to investigate. Whether the fragment would produce useful weight loss in people still had to be tested.
What did the animal research show?
A 2000 study in obese rats found less weight gain and increased fat breakdown after oral AOD9604. Insulin sensitivity did not worsen in that experiment. A 2001 mouse study also found reductions in body weight and fat, with changes involving the beta-3 adrenergic pathway. These were animal findings, not a prediction of how much weight a person would lose. Rat study; Mouse study.
A separate 2015 experiment involved 32 rabbits with chemically induced knee osteoarthritis. Joint injections of AOD9604, hyaluronic acid, or both were compared with saline. The combination had better cartilage-assessment scores and a shorter period of lameness than either treatment alone. That result supports further joint research, but it does not establish cartilage repair or pain relief in people. Rabbit study.
What happened in the human weight-loss trials?
AOD9604 did reach human trials. An earlier study involving 300 adults reported some favorable weight and waist measurements. However, the publicly available efficacy report was a conference abstract. FDA later found that the limited methods and results made its clinical importance difficult to judge. FDA evidence review.
The larger OPTIONS study was more consequential. In February 2007, the developer reported that weight loss with oral AOD9604 was not significantly different from placebo at 12 or 24 weeks. Participants also followed a diet and exercise programme. The company ended development for obesity after those results. This conclusion comes from the sponsor's trial announcement, rather than a complete peer-reviewed efficacy paper. Original company announcement.
The result does not prove that every possible formulation or use would fail. It does mean that this substantial oral trial did not establish a weight-loss benefit. Suggesting that injections would work better requires evidence for injections; it cannot be assumed from a disappointing oral result.
Research did continue after the obesity programme, under the name LAT8881, in oral and intravenous pain studies. The oral neuropathic-pain study's posted registry results did not show a significant benefit on its primary pain measure compared with placebo. Those studies concern different conditions. They do not establish weight-loss benefit or the safety of subcutaneous use. Peptide identity and protocol; Oral pain study; Intravenous pain study.
What can we say about safety?
A 2013 publication summarized six placebo-controlled studies using oral or intravenous AOD9604. It reported no significant increase in IGF-1 or adverse effect on glucose testing under the studied conditions. The authors described tolerability as similar to placebo. Two authors were affiliated with the developer, which is relevant context when reading the report. Published safety report.
Adverse events, including serious ones, did occur. The detailed report describes a serious episode of diarrhoea as possibly related to oral AOD9604. Other serious events were considered unrelated. An event during treatment does not by itself establish causation, but those details should not be replaced with a blanket claim of safety. Limited trials also cannot exclude every uncommon or longer-term risk.
FDA's current safety information identifies possible immune-reaction and peptide-quality concerns, limited safety data and serious adverse events whose relationship to AOD9604 is unclear. Its 2024 review found no human exposure data for the proposed subcutaneous or topical routes. Oral and intravenous findings therefore should not be presented as proof that a subcutaneous product is safe. FDA safety information; Route-specific review.
How should personal reports be considered?
If someone reports a change in body composition, the details matter: what changed, how it was measured, how long it lasted, and whether diet, activity or other treatments changed too. A personal account can raise a useful question, but it cannot show how often AOD9604 helps or separate its effect from those other factors.
The same care applies to claims about joint recovery. A rabbit experiment and someone's experience answer different questions. Neither substitutes for a controlled patient study of the specific product and route.
What should someone ask before considering it?
- What health problem are we trying to address, and what evidence applies to that problem?
- Is the proposed product the same peptide and route used in the evidence being discussed?
- What is known about product identity, purity and the relevant safety risks?
- Which established options have better evidence for the outcome I want?
- How would benefit, side effects and a reason to stop be assessed?
In its US review, FDA stated that neither AOD9604 free base nor its acetate form is a component of an FDA-approved drug. Pharmacy compounding and drug approval are different questions. The applicable route and jurisdiction need to be checked for a particular proposed treatment. FDA review.
AOD9604 has a real research history. The useful lesson is to keep that history intact: encouraging animal findings, limited earlier human signals, a larger negative weight-loss trial, and remaining questions about safety and other uses.
Questions people ask
Is AOD9604 the same as growth hormone?
No. It is a 16-amino-acid synthetic peptide modeled on part of growth hormone. Evidence about full growth hormone cannot simply be transferred to AOD9604.
Did AOD9604 work in the larger obesity trial?
The developer reported that oral AOD9604 did not produce statistically significant extra weight loss over placebo at 12 or 24 weeks in the OPTIONS study. Development for obesity was stopped.
Do the human trials establish that subcutaneous injections are safe?
No. The published programme used oral and intravenous administration. FDA identified limited safety information and no human exposure data for the proposed subcutaneous route in its 2024 review.
The evidence
Selected original studies and official sources. Related research is searchable on our Science page.
Sources checked November 5, 2026. Animal-study summaries are limited to their published abstracts. The human safety paper and relevant FDA review sections were checked; the larger trial's efficacy result is from the developer's announcement as reproduced in FDA's review. No article-specific medical review is claimed.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. AOD9604 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.